EVALUATION OF CANDIDATE GENETIC VARIATIONS AS PHARMACOGENETIC MARKERS FOR METFORMIN AMONG FILIPINOS

Main Article Content

Elizabeth Paz-Pacheco
Eva Maria Cutiongco-de la Paz
Jose Nevado Jr.
Gabriel Jasul Jr.
May Uyking-Naranjo
Ma. Luz Vicenta Guanzon
Karell Jo Angelique Calpito
Elizabeth Laurize Alejandro
Vincent Sean Ribaya
Julius Patrick Ferrer

Abstract

INTRODUCTION
This study aims to determine the genetic polymorphisms associated with drug response to metformin in type 2 diabetes mellitus (T2DM).


METHODOLOGY
Unmatched cases and controls were used to test the association of genetic polymorphisms in candidate genes to test drug response to metformin. Two hundred fifteen patients with type 2 diabetes who were diagnosed within the past 3 years, without recent T2DM treatment were enrolled simultaneously from three (3) hospitals from Luzon, Visayas and Mindanao and various communities around its area. The participants were started on metformin as monotherapy for 3 months. Glycosylated hemoglobin (HbA1c) was measured at baseline and after 3 months of treatment. Genotyping was done using customized Illumina Infinium microarray chips. Candidate variants were then correlated with response using logistic regression analysis.


PRELIMINARY RESULTS and DISCUSSION
There are three (3) candidate genetic variants significantly associated to metformin response in this study. The two most significant single nucleotide polymorphisms (SNPs) are variants of the gene FK506-binding protein 5 gene (FKBP5) (AA > AC > CC: OR 3.44, 95% CI 1.67, 7.76; p-value 0.0004 and CC > CT > TT: OR 3.45, 95% CI 1.64, 8.06; p-value 0.0006, respectively).


CONCLUSION
The study revealed SNPs that were not previously associated with metformin response. Genetic variation exists among Filipinos and these influence treatment responses to oral hypoglycemic agents. This study on the genetics of Filipinos with diabetes will potentially benefit the population with use of appropriate medications.

Downloads

Download data is not yet available.

Article Details

How to Cite
Paz-Pacheco, E. ., Cutiongco-de la Paz, E. M., Nevado Jr., J. ., Jasul Jr., G., Uyking-Naranjo, M., Guanzon, M. L. V., Calpito, K. J. A., Alejandro, E. L., Ribaya, V. S., & Ferrer, J. P. (2022). EVALUATION OF CANDIDATE GENETIC VARIATIONS AS PHARMACOGENETIC MARKERS FOR METFORMIN AMONG FILIPINOS. Journal of the ASEAN Federation of Endocrine Societies, 34(2), 29. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/1959
Section
Abstracts of Original Articles | Prediabetes, Diabetes Mellitus, Hypoglycemia
Author Biographies

Eva Maria Cutiongco-de la Paz, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Karell Jo Angelique Calpito, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Elizabeth Laurize Alejandro, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Vincent Sean Ribaya, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

Julius Patrick Ferrer, Institute of Human Genetics, National Institutes of Health, University of the Philippines, Manila

Philippine Genome Center, University of the Philippines,
Diliman, Quezon City

References

*

Most read articles by the same author(s)

1 2 3 4 5 6 > >>